Company / Return on Assets (ROA)
UroGen Pharma Ltd. Return on Assets (ROA) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-76.6%
FY2025
5-year range
-92.5% / -19.0%
FY2021-FY2025
Trend
-302.6%
vs FY2024
Sector context
#199 of 213
Health Care
What the data says
Return on Assets (ROA) changed -303% YoY in FY2025, a notable deviation from the 8-year average annual change of -133%.
Based on SEC 10-K filings.
-76.6% in FY2025 with a 5-year CAGR of +9.6%.
Declined from -61.6% to -76.6% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +5.1pp
- 5-Year Change
- +9.6pp
- 10-Year Change
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 213This company -76.6% Sector average -24.1%
▼
-217.2% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) decreased 302.6% year-over-year.
- Currently 52.4pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2019.
- Lowest return on assets (roa) in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -76.6% | -302.6% |
| FY2024 | -19.0% | +69.1% |
| FY2023 | -61.6% | +24.6% |
| FY2022 | -81.7% | +11.7% |
| FY2021 | -92.5% | -7.4% |
| FY2020 | -86.2% | -772.3% |
| FY2019 | -9.9% | +86.5% |
| FY2018 | -73.1% | -176.0% |
| FY2017 | -26.5% | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026